FabriceAndre @FAndreMD Twitter profile

Last Seen Profiles

@cdecaro

@rolosushi

@Friend3AI

@emmyyasha

@Bl3SG4NU

@liao_xiang96348

@SabahAyoub

@CoachTullis

@Chance_LaChappa

@EnvuGolfCA

@stwmaniax

@RadiodaysEurope

@BayerGolf

@SimrexF

@OOCSleepingDogs

@AthleticsRcc

@tripoli187

@crottylifer

@DalScience

@AUDITOREZZ

@HenryGraff

@anna_garx

@GB08099209

@stwmaniax

@hhierosuk187936

@kyapi3300

@travel_w_derek

@AOL

@Rozmond1

@animega_spparco

@LuvDoctorWho

@desianaaw12

@_Chugege_

@chengxianweek

@HeadlessVLR

@HSScotland

FabriceAndre

@FAndreMD

2 years

Thank you to the @myESMO community to have elected me President. Digital / molecular tools to optimize care & integrating science to medical decision will be the main pillars of the vision, with the aim to improve outcome, decrease tox and decrease healthcare disparities. 1/3

86

48

564

FabriceAndre

@FAndreMD

4 years

V happy to become Head of Research @GustaveRoussy : 500 staff, 10 highly cited researchers, 8 NEJM / Nature in 2019 as lead author.

Gustave Roussy

@GustaveRoussy

4 years

Le Pr Fabrice André est nommé Directeur de la Recherche de @GustaveRoussy par la Ministre des Solidarités et de la Santé @agnesbuzyn et par la Ministre de l'Enseignement supérieur, de la Recherche et de l'Innovation @VidalFrederique , pour cinq ans. ▶️

7

33

128

80

59

460

FabriceAndre

@FAndreMD

1 year

Argentina won the world cup (deserved) but the two teams together won the title of best game ever in a world cup. Thanks to them !

18

20

448

FabriceAndre

@FAndreMD

3 years

The new Impact Factor @annals_oncology is 32. It means the papers we publish are highly cited and, given our Editorial scope, probably impact patient's outcome. Remember that all articles are free for @myesmo members ! Thank you all for your contributions !

21

39

396

FabriceAndre

@FAndreMD

3 years

I'm very honored to receive the 2021 Outstanding Investigator Award for Breast Cancer Research from the American Association for Cancer Research @AACR at SABCS21.

SABCS

@SABCSSanAntonio

3 years

Helen Piwnica-Worms, PhD and Fabrice André, MD, PhD are the #SABCS21 recipients of the @AACR awards for their contributions to breast cancer research. See more at our blog.

0

21

84

46

13

347

FabriceAndre

@FAndreMD

4 years

New Impact Factor of @Annals_Oncology is 18.2. This means our articles are more and more cited every year. Thanks a lot to all the Authors, Staff, Editors and Reviewers to make our journal better. High quality publication and dissemination ultimately improves patient management

13

37

313

FabriceAndre

@FAndreMD

2 years

The presentation: "Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study" has just been added to the Presidential session III of #ESMO2022 First randomized trial testing a KRAS inhibitor in NSCLC

2

53

274

FabriceAndre

@FAndreMD

4 years

This is the best review I ve read so far in the field of AI applied to cancer pathology. If you have few minutes, you should read it at . As always with @NatRevClinOncol , the figures are outstanding

2

86

254

FabriceAndre

@FAndreMD

2 years

After 5 years, it’s time to leave the position of Editor in Chief of @Annals_Oncology . Call for applications is now open for the next EiC Tks to everyone, esp authors & reviewers. The journal has a now clear Editorial line & we are confident that we help improving patient care

13

24

254

FabriceAndre

@FAndreMD

4 years

. @GustaveRoussy ranked 5th oncology hospital in the world by @Newsweek We all know the limitations of these rankings and that all big centers are very similar, but it probably means we are doing a good work for pts and research …

11

46

237

FabriceAndre

@FAndreMD

3 years

we are very pleased to announce that papers published in @Annals_Oncology are now free for patients. thanks @myESMO and @ELS_Oncology . To get a paper; go to and request it thanks to the link mentioned below

12

61

221

FabriceAndre

@FAndreMD

3 years

we have been AGAIN forbidden to share our genomic data on open portals, because of the "per-project re-consent" of GDPR. Frustrating for pts, clinicians and researchers who want to share their data to generate societal advances. Claim for open science is not compatible w GDPR

17

55

209

FabriceAndre

@FAndreMD

4 months

Metastatic cancers should be classified as much as possible based on their biology, and agnostic of organ of origin To reach this vision, new statistical tools are needed to claim that drugs work across multiple cancers TY @Nature & @lucy_os for the opportunity to write about it

nature

@Nature

4 months

The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them. We need radical changes in how medical oncology is structured, conducted, and taught

8

111

277

15

72

203

FabriceAndre

@FAndreMD

2 years

To authors who submit a paper @Annals_Oncology ; there is a procedure for presubmission inquiry. you can get a quick answer without formatting your paper. it's waste of resources if brains who should focus on research & care spend hours to format ms rejected without review.

2

30

203

FabriceAndre

@FAndreMD

4 months

Tk you @Thelancet for taking this question seriously. Academic clinical trials should be evaluated mainly based on their IMPACT on pts, not only on innovation. Too many grant committees give too much weight to innovation vs impact , when it’s about funding clinical trials

The Lancet

@TheLancet

4 months

On our cover this week ⬇ A Viewpoint on the need for pragmatic, affordable, and practice-changing real-life clinical trials in #oncology : Full issue in thread 🧵

23

155

391

5

50

204

FabriceAndre

@FAndreMD

3 years

In the next 10 d, I m going to comment 10 important papers published in @Annals_Oncology in 2020. before starting; Annals has an editorial line: "driving innovation in oncology". it defines the journal's identity and the frame of acceptance. 150 original papers are published / y

4

31

200

FabriceAndre

@FAndreMD

3 years

I'm very happy to co-chair with @CharlesSwanton the Scientific Program @myESMO Annual Meeting 2022. More info soon about Editorial Line & preliminary program. The scientific committee is outstanding. We look forward to see you in Paris on sept 9th 2022

6

27

201

FabriceAndre

@FAndreMD

3 years

I have the task to animate a live discussion about a drug that gives HR:0.28 and is not toxic. 😬 Can anyone help me finding conversation piece about it ?? or maybe we take the opportunity to discuss about things since there is no controversy here; just give the drug #ESMO2021

26

20

191

FabriceAndre

@FAndreMD

2 years

Targeting cancer complexity is going to be tough. I see three options: treat cancer before it becomes complex , discover the molecular roots of complexity, treat different compartments separately (ADC could help). #AACR22

11

27

184

FabriceAndre

@FAndreMD

2 years

we have now implemented a Plain Language Summaries of @Annals_Oncology for patients, students and in general for everybody who want to learn without going deep. Thanks to the Pt Advocacy and Young Oncologists WG of @myESMO

10

52

178

FabriceAndre

@FAndreMD

10 months

DAISY trial (TDXD) @NatureMedicine : 29% OR in pts Her2=0 but only 4 months PFS Her2=0: pts w ultralow ERBB2 by RT-PCR present ORs No uptake of TDXD by tumor in Her2=0 vs uptake in Her2+ No quantitative change of immune cells drg TDXD Uptake of TDXD in 4/6 samples at resistance

3

55

175

FabriceAndre

@FAndreMD

25 days

.⁦ @myESMO ⁩ is launching a monthly virtual journal club. 3 papers discussed during 1h by the best experts. The goal is to update all colleagues about the latest advances wherever they are in the 🌍. First session on May ! Stay connected !

ESMO Virtual Journal Club

www.esmo.org

2

37

176

FabriceAndre

@FAndreMD

3 years

This is an incredible paper. I can just imagine how many hours authors have spent to write it and to draw the figures. outstanding effort. Obviously anyone involved in BC care and translationel research should read it

Giampaolo Bianchini

@BianchiniGP

3 years

📢Proud to present our manuscript 'Treatment landscape of triple-negative breast cancer — expanded options, evolving needs' which has just been published with @SpringerNature in @NatRevClinOncol If you are intrested read here: #bcsm #TNBC @OncoAlert

21

213

561

6

38

172

FabriceAndre

@FAndreMD

3 years

The 1st ⁦ @myESMO ⁩ guidelines on metastatic breast cancer have just been published with some important messages about the positioning of tdxd , palb2 mutations, alpelisib , IO and adc in tnbc... under the great leadership of Alessandra Gennari

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metast...

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have been reported with appropriate therapeutic strategies.1-8 Systemic therapy is the standard-of-care in MBC but...

www.annalsofoncology.org

5

73

170

FabriceAndre

@FAndreMD

4 years

Cannabis extracts seem effective to prevent chemo-induced nausea and vomiting. I love the conclusion: "participants preferred cannabis to placebo" 😅

7

52

171

FabriceAndre

@FAndreMD

4 years

6 month improvement in OS in late line. HR:0.48 for OS. Sacituzumab govitecan is going to substitue chemo very soon in all settings, including (neo)adj of TNBC #ESMO20

8

40

169

FabriceAndre

@FAndreMD

3 years

JD Flaysakier etait mon etudiant en these et une aide precieuse pour la dissemination scientifique. Une boite a idee, un vrai chercheur en cancero. Son projet c’etait de connecter questions simples et rigueur scientifique. On rigolait svt, il est parti avec ttes ses anecdotes...

Gustave Roussy

@GustaveRoussy

3 years

Nous apprenons avec tristesse le décès du Dr Jean-Daniel Flaysakier, grand journaliste #sant é et vulgarisateur hors pair. Il nous avait rejoints en 2018 pour participer à des recherches sur le cancer du sein et préparer une thèse. Toutes nos pensées à sa famille et à ses proches.

2

71

311

3

25

167

FabriceAndre

@FAndreMD

5 years

CDK4/6 inhibitor to prevent ... neutropenia (!!!!) induced by chemo. A randomized trial. I m lost with this drug family: it induces neutropenia as single agent and prevents neutropenia when given with chemo 🤔

11

51

157

FabriceAndre

@FAndreMD

3 months

We know how will be the next Research Building @GustaveRoussy (Q1 2027) 32 000 m2 , 60 research teams in 15 Centers, 15 core facilities, 1400 staff. Each floor will include 10 teams of biology that will surround Data Science / Epidemiology teams. We are welcoming new teams !

7

14

161

FabriceAndre

@FAndreMD

2 years

(Through jp armand)

3

44

157

FabriceAndre

@FAndreMD

5 years

v proud to be author of this paper. A work done with large number of colleagues and friends. Tks to Editors and reviewers who improved it a lot. special mention to pts who accepted to receive a biopsy for research and to donors who funded this work through charities (and taxes🤷🏻‍♂️)

Eric Topol

@EricTopol

5 years

The #genomics of metastatic breast #cancer : analysis of 617 patients demonstrates sheer complexity as tumors evolve and spread @nature by @FAndreMD and collaborators

2

80

140

1

44

153

FabriceAndre

@FAndreMD

9 months

Pooled ctDNA analysis of MONALEESA -02, -03, -07 trials. >1000 pts analysed. ANO1, CDKN2, RB1 and high TMB associated with lower sensitivity to ribociclib.

3

47

152

FabriceAndre

@FAndreMD

1 year

. @PrismCenter selected to receive 30-40 M euros to build a Precision Oncology Center. Vision: to classify pts based on biology. Scientific strategy: bottom-up approach to model cancer biology in each pt (fig 2) for early cancer or relapse detection, & tt optimisation (fig 3).

13

38

152

FabriceAndre

@FAndreMD

3 years

The 5 year OS wall has been broken by Ribo for pts with endocrine sensitive stage IV BC . A milestone in oncology. When I saw the data first time, it came to my mind the very low 5 y OS I was learning when I was student #ESMO21

1

23

151

FabriceAndre

@FAndreMD

7 years

v proud to have been nominated Chief Editor of @Annals_Oncology . thanks @myESMO . @jsoriamd did an incredible job

19

33

151

FabriceAndre

@FAndreMD

3 years

Tumor Mutational Burden predicts sensitivity to anti-PD1 .... only in cancers where CD8 T cell infiltration correlates with tumor neoantigens. No association between TMB and anti-PD1 activity across tumor types (n=1500 and 1900) (cat I/II: CD8 infil 👇🏼)

4

46

149

FabriceAndre

@FAndreMD

3 years

Petit Palais was nice yesterday for the @myESMO diner #ESMO21 . We 🤞 that more people will be allowed to attend « ESMO22 Paris » next year

9

7

144

FabriceAndre

@FAndreMD

2 years

To attendees of #SABCS21 ; I m very sorry for not having been able to make the presentations SAFIR02 and AACR award (friday) in person, but a member of my close family was tested covid+ on saturday (everything OK); so I was not allowed to travel. I hope it's OK by virtual

10

0

142

FabriceAndre

@FAndreMD

4 years

I'm not comfortable with the terminology "Virtual conference". It's a real conference that is digital. can't we call it "Digital conference" ? virtual would mean that all what is presented does not exist... like when my team beats barcelona on Nintendo Switch... #ESMO20

11

5

140

FabriceAndre

@FAndreMD

7 months

Tonight I had the opportunity to diner with Bob Pinedo, a Legend of Cancer research. A lot to discuss: cisplatin developt by Cvitkovic, 1st bone marrow transplant by Mathe, his developt of azacitidine. Also how 70-80’s were driven by creativity rather than technology. #ESMO23

4

7

140

FabriceAndre

@FAndreMD

3 years

Pembrolizumab improves EFS, and clearly reduces the rate of metastatic relapse in patients with eTNBC, irrespective to PDL1 expression. A transformation for future patients. We hope this drug will be accessible very quickly for the patients who need it

4

52

138

FabriceAndre

@FAndreMD

5 years

A BIG thanks at @partitadelcuore , @FilippoMontemu1 and Ms Agnelli for having invited me to this incredible event. Continue donating at 45527 for Cancer Research ! First time ever Ronaldo-Pirlo-Totti-Nedved in the same team !

13

20

131

FabriceAndre

@FAndreMD

2 years

SAFIR02 breast trial: benefit (HR:0.41) of using genomics in pts with ESCAT I/II (Condorelli, Ann Oncol + Tung, JCO). No detectable benefit ESCAT >I/II (small size). This ranking could be used in clinics, and amended stepwise when new targets come 1/3

Victoria Aranda

@mvicaracal

2 years

Warming up for #ESMO22 , online at @nature : “Genomics to select treatment for patients with metastatic breast cancer” by @FAndreMD and colleagues . With our brand new #clinicalbriefing

1

6

29

5

35

135

FabriceAndre

@FAndreMD

1 year

T-dxd improves PFS compared to treatment of physician’s choice in pts with Her2-overexpressing mBC resistant to TDM1. Median PFS: 6 > 17 months (HR:0.36, 0.28-0.45) (DESTINY-B02). Evidence that an ADC can reverse resistance to another one. In @TheLancet

3

23

132

FabriceAndre

@FAndreMD

4 years

18% of pts included in PALLAS did not receive adj chemo. What happens in the brain of an oncologist who considers that a pt has a risk high enough to receive a CDK4 inh for 2 years... but does not give adjuvant chemo ????? #ESMO20

18

27

130

FabriceAndre

@FAndreMD

1 year

Petite pensee a @kinkybambou , patiente qui a fortement contribue a developper la Vision de @PrismCenter labellisé IHU ce jour. @kinkybambou est malheureusement decedee il y a quelques semaines. Elle aurait tellement aime cette nouvelle

Gustave Roussy

@GustaveRoussy

1 year

« Le Centre national de médecine de précision #PRISM entre dans une nouvelle dimension en devenant un Institut Hospitalo-Universitaire » 📰 Lire le #Communiqu éDePresse ⤵️

0

13

33

2

28

130

FabriceAndre

@FAndreMD

4 years

. @jsoriamd is the new general director of @GustaveRoussy ! roadmap and vision expected for Q1. (👇🏼w george mathe )

7

28

124

FabriceAndre

@FAndreMD

5 years

very proud to be in this list with 10 colleagues and friends. these 11 account for >10% of the highly cited researchers working in life science in 🇫🇷 😳. @GustaveRoussy is an outstanding institute.

Gustave Roussy

@GustaveRoussy

5 years

🏆11 médecins-chercheurs de @GustaveRoussy figurent dans la liste 2018 @clarivate @webofscience des chercheurs les plus cités au monde, une performance pour une structure française ! Pour les découvrir 👉 #HighlyCitedResearchers #HighlyCited2018

0

34

72

13

25

124

FabriceAndre

@FAndreMD

4 years

A cancer patient from @GustaveRoussy presenting a symptomatic covid infection, treated with an anti IL6R antibody. could be useful to some (not all) patients. prospective trials will inform us about predictive markers of efficacy. @AlbigesL @MichotJM

8

66

123

FabriceAndre

@FAndreMD

6 months

Aside trials testing Innovations, there is a need for trials testing pragmatic questions in oncology. These trials must ↘️↘️ the nb of data collected & bureaucracy. This is 1 of the 4 pillars of clinical research strategy @GustaveRoussy 1/2

The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology

Thanks to technological advances and improved understanding of cancer biology, clinical research in oncology has become increasingly complex. Trials testing novel interventions are subject to...

www.thelancet.com

3

41

122

FabriceAndre

@FAndreMD

5 years

incredible emotion when we visited the @royalsociety w the faculties of MAP2019. we had access to the original "principles of mathematics" (Newton), the 1st edition of the origins of species and others. these books have transformed the world. vertiginous. tk @CharlesSwanton

1

11

119

FabriceAndre

@FAndreMD

3 years

PI3K inhibitors are finally coming of age, by ⁦ @CellsigL ⁩ . everything you need to know about PI3K inhibitors : 377 references !!!! and nice illustrations .

2

29

118

FabriceAndre

@FAndreMD

5 years

1st large prospective study looking at PRO before / after breast cancer. n=4 000, 1st set of CANTO (n=12 000). Key msg; Endocrine therapy dramatically alters PRO (more than chemo in post-meno pts); there is an urgent need to de-escalate ET : biomarkers !

3

56

111

FabriceAndre

@FAndreMD

2 years

How a failed clinical trial led to an important discovery, in @Nature PI3K delta inh ↘️ T reg infiltration in tumor (1), particularly an ST2-like T cell pop (pop 8 in 2). T reg ↘️ induces colitis. Intermittent schedule ↗️ results.

2

26

114

FabriceAndre

@FAndreMD

4 years

we must find solutions to make careers of clinician scientists more attractive. CS are the ones translating basic concepts and innovation to patients. need for action @esmo @aacr @ASCO . V proud to sign this paper w @LoiSher @CRUKresearch @CharlesSwanton

Securing the future of the clinician-scientist

Nature Cancer - By integrating discovery science with clinical practice and therapeutic intervention, clinician-scientists fulfil a unique role in cancer research. However, their numbers are in...

www.nature.com

2

53

117

FabriceAndre

@FAndreMD

4 years

Synthetic control arms are coming in oncology. It will allow pts to get quicker access to innovation and avoid randomisations. One of the 1st examples (post-hoc) is now published in @Annals_Oncology ,comparing APT trial with external controls. @stolaney1

A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and...

Although the Adjuvant Paclitaxel and Trastuzumab (APT) trial has been adopted clinically, single-arm trials have limitations, and interest remains whether these patients with small node-negative...

www.annalsofoncology.org

5

49

117

FabriceAndre

@FAndreMD

2 years

Intense grant writing ⚽️

2

0

114

FabriceAndre

@FAndreMD

4 years

Three no-show (so far) during covid19 crisis: WHO AI peer reviewing

7

27

114

FabriceAndre

@FAndreMD

3 years

2nd trial showing that fecal transplant overcomes resistance to anti-PD1. The proof-of-concept is now done. next step will be to transform this into a therapeutic strategy. drug-bacteria or fecal transplant ???

4

38

115

FabriceAndre

@FAndreMD

4 years

Some patients treated with anti-CD20 antibody present a very severe chronic COVID infection requiring long stay in ICU, due to lack of B cells. It's absolutely crucial to avoid COVID infection in these patients.

6

34

110

FabriceAndre

@FAndreMD

5 years

🚨🚨⚽️⚽️V Happy to take part in @partitadelcuore . May 27th, 8pm @juventusfc stadium and @RaiUno . coach: M Platini 😍😍. tks @FilippoMontemu1 . Part of the benefits will go to Fondazione Piemontese Ricerca Sul Cancro. pls give at 45527 !!! I trained hard dg the last 2 months!

17

11

110

FabriceAndre

@FAndreMD

2 years

In ⁦ @JCO_ASCO ⁩ ; Guidelines for the use of biomarkers in pts with early stage BC. A huge work done with @VeredStearns , coll and pts. Key msg: only oncotype in premeno pts, Ki67:✅ in some situations, no biomarkers in >3N+, tnbc, her2.

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline...

PURPOSE To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer. METHODS An updated...

ascopubs.org

2

46

112

FabriceAndre

@FAndreMD

2 years

Ballot for the esmo tournament has been done today by @CharlesSwanton , the Chair of @myESMO scientific committee 2022 ! And some groups are tough 😰

3

7

108

FabriceAndre

@FAndreMD

5 months

In a few weeks, I ll no longer be Editor in Chief of @Annals_Oncology . In this Editorial, some reflections about this period and how the journal was transformed. tks to authors, readers, editors, reviewers, @ElsevierConnect , @myESMO , lewis & @jsoriamd

1

12

108

FabriceAndre

@FAndreMD

1 year

@Celinextenso @kinkybambou tres triste, @kinkybambou a monte avec nous le dossier de Centre de Medecine de Precision PRISM (en evaluation). Son experience a ete cruciale pour definir la vision: « les cancers doivent etre definis et representes par leurs mecanismes biologiques » et la partie pt engagement

0

8

107

FabriceAndre

@FAndreMD

2 years

Single Cell Atlas of Breast Cancer. A must read. @gustaveroussy is v proud to have contributed to this International effort through our expertise in myeloid cells ( @cadutertre & @FGinhoux ). Identification of Lipid-Associated Macrophages in Breast Cancer👇

0

32

109

FabriceAndre

@FAndreMD

6 years

The paper that everyone was expecting; role of Tumor Mutational Burden as biomarker for IT, written by the key people of the fiel; ⁦ @peters_solange ⁩ ⁦ @CharlesSwanton ⁩ ⁦ @squezadd ⁩ T Chan .... v comprehensive, nice fig. key msg: read it !

1

65

108

FabriceAndre

@FAndreMD

4 years

🇮🇹 Forza Italia

Aurélie Casse

@AureCasse

4 years

Quelle image ! De tout cœur avec vous, les Italiens !

497

7K

25K

3

16

108

FabriceAndre

@FAndreMD

3 years

The Annual meeting of @myesmo 2022 will be in Paris. Given the burden of innovation in oncology, it's expected to have an outstanding program, full of hope for patients, doctors, nurses, researchers and the whole community !

1

11

107

FabriceAndre

@FAndreMD

3 years

Detection of ctDNA at the time of cancer diagnosis: 99.5% spec & 51% sens. promising in pancreatic cancer. 88% prediction of tissue of origin. the test is now available in US. next step: evidence it detects some cancers earlier than standard of care ?

Clinical validation of a targeted methylation-based multi-cancer early detection test using an...

A multi-cancer early detection (MCED) test used to complement existing screening could increase the number of cancers detected through population screening, potentially improving clinical outcomes....

www.annalsofoncology.org

4

48

106

FabriceAndre

@FAndreMD

2 years

. @Annals_Oncology has reached a new milestone. While the Editorial policy is to publish <10 articles a month, the nb of downloads has dramatically increased to >1 M per month drg several consecutive months. This means that papers we publish are read by a large number worldwide

0

13

104

FabriceAndre

@FAndreMD

8 months

ADCs are substituting chemo step by step. Here, the 24-month findings from the trial of enfortumab vedotin vs chemo in pts with advanced urothelial carcinoma. The big question in this field is the impact of ADCs in pts with early stage cancers

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus...

This exploratory analysis evaluated efficacy and safety data for enfortumab vedotin versus chemotherapy over a median follow-up of ∼2 years from EV-301.

www.annalsofoncology.org

1

29

104

FabriceAndre

@FAndreMD

4 years

.⁦ @myESMO ⁩ reco for NGS 1. Public health: NSCLC, cholangio, prostate, ovarian Kc: ✅ + TMB in 5 add cancers. Optional CRC 2. Clin res centers: any pt eligible for trial 3. pt centric (outside 1): ✅if pt aware of v low benefit and no cost /public HS

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic...

Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no...

www.annalsofoncology.org

2

45

100

FabriceAndre

@FAndreMD

4 years

Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: 60% pathological complete response, high TILs and/or PDL1 = higher pCR. by P Schmid, @LoiSher and coll

1

46

101

FabriceAndre

@FAndreMD

5 years

to my colleagues researchers and +++ reviewers and editors; a paper showing that Cas9 itself mediates tumor rejection by T cell. A MAJOR source of biases in immuno-oncol projects.

SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice

The CRISPR/Cas9 system has recently emerged as a highly efficient modality in genetic engineering and has been widely considered for various therapeutic applications. However, since the effector pr...

www.tandfonline.com

4

55

99

FabriceAndre

@FAndreMD

3 months

Merci a tous les soutiens pour mon #SemiParis au profit de @GustaveRoussy . Le parcours est genial mais la fin est hyper dure a cause des crampes 😩🥵

3

5

100

FabriceAndre

@FAndreMD

4 years

serum detection of tamoxifen: 16% non adherence at 1 year; associated with relapse. In this study, it s estimated that non-adherence could contribute to around 20% of relapses. A study from CANTO project by @BarbaraPistill2 and @inesvazluis

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk

PURPOSE Nonadherence to long-term treatments is often under-recognized by physicians and there is no gold standard for its assessment. In breast cancer, nonadherence to tamoxifen therapy after...

ascopubs.org

1

51

96

FabriceAndre

@FAndreMD

4 years

I would love to see an ImpAscent trial that would combine anti-TROP2 ADC and anti PD(L)1 antibody. According to what we know about biology (Ag release, immunogenic cell death, Lymphocyte sparing by ADC), it should transform TNBC. #ESMO20

3

22

96

FabriceAndre

@FAndreMD

6 years

I was v happy to receive the San Salvatore award, especially one year after @CharlesSwanton , but I felt even more happy when I received so many 👍🏼💪🏼👏🏼🤙🏼♥️after. thanks ! I feel like the @riouyoann of oncology

11

7

97

FabriceAndre

@FAndreMD

4 years

Primary endpoint of 5 phase III randomized trials will be presented during @myESMO 2020, including 1st ADC in TNBC and 1st adjuvant trials testing cdk4/6 inh.

Kevin Punie

@kevinpunie

4 years

🚨Less then 🔟days before the start of virtual #ESMO20 and 2⃣weeks before the start of the science weekend, besides looking forward to our #YoungOncologistCommittee track, i'm eagerly awaiting so many new exciting data in #breastcancer My top 10 selection🤗 👇 @OncoAlert @myESMO

1

40

83

1

37

98

FabriceAndre

@FAndreMD

4 years

<5 years from 1st patient dosed to @FDAOncology approval. Beside its efficacy this drug probably opens an era of translational research in the field of intracellular trafficking to understand how payload reaches its target

FDA Oncology

@FDAOncology

4 years

Today the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (ENHERTU®, Daiichi Sankyo) for patients with unresectable or metastatic HER2-positive breast cancer who received two or more anti-HER2-based regimens in the metastatic setting

1

17

41

0

25

95

FabriceAndre

@FAndreMD

2 years

@bradloncar Without disclosing what will be presented, #ESMO22 will be for sure a conference that colleagues will remember 20 years after , given the wealth of innovation + new concepts on the clinical trials side

5

9

96

FabriceAndre

@FAndreMD

4 years

Effect of containment: +46% paper submissions to @Annals_Oncology in March...😓

9

15

97

FabriceAndre

@FAndreMD

3 years

I was so proud to have met @EmmanuelMacron that I sent a pic to one of my sisters. here is the answer 🙄

3

4

94

FabriceAndre

@FAndreMD

2 years

For those who want to play football, we organise a game on monday 6 pm during @ASCO conference. Pls send me an e-mail. NB: @DrChoueiri being out of shape , he will not attend 🧸 😏

6

4

96

FabriceAndre

@FAndreMD

3 years

We have now a cute vegetable garden @GustaveRoussy . It��s like an Oasis in the middle of Buildings hosting sad human stories. I can see colleagues taking care of it sometimes when they want to breath a little bit

4

5

93

FabriceAndre

@FAndreMD

4 years

Good morning from the virtual, parallel world

6

1

95

FabriceAndre

@FAndreMD

5 years

Very important paper showing high sensitivity to anti-PD1 single agent in patients with >90% PDL1 NSCLC. Need for an additional biomarker (TMB ? CD8 ?) to reach outlier sensitivity, and withhold chemo. work in progress. tks @DrMarkAwad for having chosen Annals to publish it !

Mark Awad

@DrMarkAwad

5 years

How do patients with NSCLC & very high PD-L1 levels ≥90% do with 1st-line pembrolizumab? Multi-institutional collaboration led by outstanding Elizabeth Jimenez Aguilar & Biagio Ricciuti now online @Annals_Oncology @BiagioMD @Elizabethjimag @DanaFarber

2

50

103

1

22

94

FabriceAndre

@FAndreMD

4 years

21h; les chercheurs de @GustaveRoussy sont mobilises pour identifier des cibles therapeutiques dans la maladie a covid19. Cytometrie de masse pour caracteriser la reponse lymphocytaire a l'echelle unicellulaire.

1

26

94

FabriceAndre

@FAndreMD

3 years

So sad Jose Baselga is dead. Beside he was very inspiring, we had a lot of fun. Our last jokes were these FIF19 @FCBarcelona / @ogcnice virtual games trying to hit as many goals as possible. let's try to score more than 100 goals jose !

AACR

@AACR

3 years

José Baselga, MD, PhD— revered AACR Past President, Fellow of the AACR Academy, and an internationally renowned expert in the development of molecular targeted agents— has died at the age of 61. We offer heartfelt condolences to his family, colleagues, and friends. #AACRFellows

27

218

800

0

4

94

FabriceAndre

@FAndreMD

3 years

. @myESMO virtual plenary is clearly the way to go: 1h session during the lunch, original data with some suspense, update on a key topic, no need to wait months before seeing data and implementing them. It will be the standard soon

4

16

95

FabriceAndre

@FAndreMD

2 years

Because there is NO reason why simple clinical trials would cost a lot 💶; ⁦ @GustaveRoussy F⁩ & @criscancer start the «Real-Life Trials in oncol Prog». 1.5 M to fund several simple 🇪🇸🇫🇷 clinical trials answering questions that impact pts 👇

Real-Life Trials in Oncology Programme | Gustave Roussy

Real-Life Trials in Oncology ProgrammeCall for Applications 2023A joint call between Gustave Roussy Foundation and CRIS Cancer Foundation. Introduction Clinical research represents the tool to...

www.gustaveroussy.fr

3

19

94

FabriceAndre

@FAndreMD

2 years

Concluding remarks of #ESMO22

President Biden

@POTUS

2 years

I believe we can end cancer as we know it and even cure cancers once and for all.

22K

14K

147K

1

10

92

FabriceAndre

@FAndreMD

3 years

One of the most robust study on clinical utility of assessing residual disease by ctDNA . >500 patients with bladder cancer from adjuvant Imvigor trial

3

20

94

FabriceAndre

@FAndreMD

3 years

This is a very very sad news. Angelo was an incredibly nice person. Always quiet, smiling and helpful. I learnt a lot from him during our work @BIGagainstBC . Also, he was so elegant and charismatic (credit photo: BIG , Brussels 2012)

BIG against BC

@BIGagainstBC

3 years

It is with great sadness that we just learned of Angelo Di Leo's passing, a brillant oncologist, a colleague and a dear friend to many of us. He will be greatly missed. Our sincere thoughts go to Laura and his daughter.

5

12

76

4

8

93

FabriceAndre

@FAndreMD

4 years

A selection of 10 papers related to breast cancer published in the last 12 months in @Annals_Oncology . thanks to the authors for trusting us to disseminate their research.

Annals of Oncology

@Annals_Oncology

4 years

With #ESMOBreast20 just around the corner, Annals of Oncology has prepared a collection of most read #BreastCancer articles. Free access using this link: #bcsm @myESMO

0

74

138

0

37

94

FabriceAndre

@FAndreMD

3 years

. @GustaveRoussy launches its center for early cancer detection, led by S. Delaloge. For participants with high risk of cancer; individualized intervention + inclusion in a research cohort to discover methods of cancer detection (plasma, feces, imaging...). 1st step: n=10 000 pts

1

28

92

FabriceAndre

@FAndreMD

5 years

key findings of the below paper in the context of other important works (mskcc, dfci, erasmus, aurora): RB1 mut> enriched in hr+ mBC, poor outcome, resistance to cdk4. 1500 pts from 3 randomized trials analyzed in the paper. soon a level I marker👇🏼

Genomic characterization of metastatic breast cancers

Nature - Patient data from six clinical trials are used to compare the genomic landscapes of breast cancer metastases with those of primary tumours, revealing an increase in mutational burden and...

www.nature.com

2

37

92

FabriceAndre

@FAndreMD

3 years

Making sense of mutations detectable in normal tissue is going to become soon a major stake in cancer research

2

14

90

FabriceAndre